Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy

BACKGROUND: Although chimeric antigen receptor (CAR)-T cell therapy has been remarkably successful for haematological malignancies, its efficacy against solid tumors is limited. The combination of CAR-T cell therapy with immune checkpoint inhibitors (CPIs), such as PD-1, PD-L1, and CTLA-4 antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yajun, Wang, Pei, Wang, Tengjiao, Fang, Yuan, Ding, Yongmei, Qian, Qijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890961/
https://www.ncbi.nlm.nih.gov/pubmed/33602263
http://dx.doi.org/10.1186/s12967-021-02750-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890961/
https://www.ncbi.nlm.nih.gov/pubmed/33602263
http://dx.doi.org/10.1186/s12967-021-02750-4

Ejemplares similares